siRNA therapy reduces triglycerides in patients with uncommon problem

.RESEARCH STUDY FEATURE.19 September 2024.

Plozasiran decreased triglyceride levels through 80% as well as reduced the threat of pancreatitis in people with chronic chylomicronemia, with or even without a genetic prognosis.